If pharmaceutical companies are working on marijuana-based drugs or their synthetic equivalent, they should be applauded for researching the medical benefits of pot and for developing treatments legally available to patients whose home states do not allow smokable medical marijuana. Great, grand wonderful. Why should anyone fear new medicine for the chronically ill? NORML is way off base for protesting the rescheduling of marijuana-derived pharmaceuticals from Schedule I to Schedule III.